Climb Bio, Inc.

NASDAQ:CLYM

Biotechnology

Healthcare
$9.30 +0.17%

+$0.02 today

Market cap
$546.27M
Beta
0.10
P/E (TTM)
-14.7
EPS (TTM)
-$0.77
52W Low $1.17High $12.48

Volume 0.87M

Average 0.88M

CLYM Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Climb Bio, Inc.NASDAQ: CLYM

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow dips below year-ago levels

Q1 FY2026 free cash flow of $14.38M (cash outflow) fell 6.8% year over year, behind the +83.3% change in trailing-twelve-month free cash flow. Sequentially, it fell 8.0% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.

Context

  • Free cash flow grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -6.8% toward the trailing-twelve-month pace of +83.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.38M-8.0% QoQ
Last fiscal yearDec 2025
-$54.54M+250.5% YoY
LTMMar 2026
-$53.49M+83.3% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.8%——
1 year+250.5%——
3-year CAGR+13.4%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(54.54M) USD
Year-over-year change
-250.5%

Free Cash Flow vs competitors

How CLYM compares with its peers on the latest reported figures

  • CLYM's LTM Mar 2026 free cash flow of $53.49M is the smallest of the 5 companies compared; the peer median is $141.51M.
  • Its year-over-year change of +83.3% is the highest of 5, against a peer median of +36.8%.
  • Over three fiscal years its annual growth of +13.4% compares with a peer median of +39.4%.
CLYM Competitors Peer median
Free Cash Flow for CLYM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CABACabaletta Bio, Inc.LTM Mar 2026$143.28M +47.4%+39.4%—
TRAXFirst Tracks Biotherapeutics IncFY2025$143.01M +13.4%——
UPBUpstream Bio, Inc.LTM Mar 2026$140.01M +68.1%+91.1%4214.6%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$68.89M +26.2%+29.9%—
CLYMClimb Bio, Inc.LTM Mar 2026$53.49M +83.3%+13.4%—
Peer median (excluding CLYM) $141.51M+36.8%+39.4%4214.6%

Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47.48M)(45.24M)(35.12M)(73.9M)(59.85M)
Depreciation & Amortization000097K
Deferred Income Tax00000
Stock-Based Compensation3.74M6.99M12.81M5.56M8.05M
Change in Working Capital(4.17M)210K3.76M1.7M(601K)
Accounts Receivables00000
Inventory00000
Accounts Payables318K(653K)(686K)(1.14M)1.56M
Other Working Capital(4.49M)863K4.45M2.84M(2.17M)
Other Non-Cash Items11.84M674K(2.05M)51.08M(2.06M)
Operating Cash Flow(36.07M)(37.37M)(20.6M)(15.56M)(54.36M)
Capital Expenditures0000(186K)
Acquisitions (Net)00000
Purchases of Investments(114.97M)(87.96M)(58.45M)(132.2M)(108.08M)
Sales of Investments0122.4M127.43M20.75M111.1M
Other Investing Activities000(9.65M)0
Investing Cash Flow(114.97M)34.44M68.98M(121.09M)2.83M
Debt Repayment00000
Common Stock Issued83.14M0841K119.75M(21K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities149K0010.98M0
Financing Cash Flow177.23M0841K130.73M(21K)
Effect of Forex Changes245K(408K)304K42K0
Net Change in Cash26.44M(3.34M)49.53M(5.88M)(51.54M)
Free Cash Flow(36.07M)(37.37M)(20.6M)(15.56M)(54.54M)

Climb Bio, Inc.

NASDAQ:CLYM

Intrinsic Alpha fair value

Locked

Current Price

$9.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.